» Articles » PMID: 37569428

The Combined Metabolically Oriented Effect of Fucoidan from the Brown Alga and Its Carboxymethylated Derivative with 2-Deoxy-D-Glucose on Human Melanoma Cells

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Aug 12
PMID 37569428
Authors
Affiliations
Soon will be listed here.
Abstract

Melanoma is the most aggressive and treatment-resistant form of skin cancer. It is phenotypically characterized by aerobic glycolysis that provides higher proliferative rates and resistance to cell death. The glycolysis regulation in melanoma cells by means of effective metabolic modifiers represents a promising therapeutic opportunity. This work aimed to assess the metabolically oriented effect and mechanism of action of fucoidan from the brown alga (ScF) and its carboxymethylated derivative (ScFCM) in combination with 2-deoxy-D-glucose (2-DG) on the proliferation and colony formation of human melanoma cell lines SK-MEL-28, SK-MEL-5, and RPMI-7951. The metabolic profile of melanoma cells was determined by the glucose uptake and Lactate-Glo assays. The effect of 2-DG, ScF, ScFCM, and their combination on the proliferation, colony formation, and activity of glycolytic enzymes was assessed by the MTS, soft agar, and Western blot methods, respectively. When applied separately, 2-DG (IC at 72 h = 8.7 mM), ScF (IC at 72 h > 800 µg/mL), and ScFCM (IC at 72 h = 573.9 μg/mL) inhibited the proliferation and colony formation of SK-MEL-28 cells to varying degrees. ScF or ScFCM enhanced the inhibiting effect of 2-DG at low, non-toxic concentrations via the downregulation of Glut 1, Hexokinase II, PKM2, LDHA, and pyruvate dehydrogenase activities. The obtained results emphasize the potential of the use of 2-DG in combination with algal fucoidan or its derivative as metabolic modifiers for inhibition of melanoma SK-MEL-28 cell proliferation.

Citing Articles

Structure and Metabolically Oriented Efficacy of Fucoidan from Brown Alga in the Model of Colony Formation of Melanoma and Breast Cancer Cells.

Usoltseva R, Zueva A, Malyarenko O, Anastyuk S, Moiseenko O, Isakov V Mar Drugs. 2023; 21(9).

PMID: 37755099 PMC: 10532595. DOI: 10.3390/md21090486.

References
1.
Navale A, Paranjape A . Glucose transporters: physiological and pathological roles. Biophys Rev. 2017; 8(1):5-9. PMC: 5425736. DOI: 10.1007/s12551-015-0186-2. View

2.
Li X, Gu J, Zhou Q . Review of aerobic glycolysis and its key enzymes - new targets for lung cancer therapy. Thorac Cancer. 2015; 6(1):17-24. PMC: 4448463. DOI: 10.1111/1759-7714.12148. View

3.
Luthuli S, Wu S, Cheng Y, Zheng X, Wu M, Tong H . Therapeutic Effects of Fucoidan: A Review on Recent Studies. Mar Drugs. 2019; 17(9). PMC: 6780838. DOI: 10.3390/md17090487. View

4.
Fischer G, Gopal Y, McQuade J, Peng W, DeBerardinis R, Davies M . Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications. Pigment Cell Melanoma Res. 2017; 31(1):11-30. PMC: 5742019. DOI: 10.1111/pcmr.12661. View

5.
Sim S, Shin Y, Kim H . Fucoidan from Undaria pinnatifida has anti-diabetic effects by stimulation of glucose uptake and reduction of basal lipolysis in 3T3-L1 adipocytes. Nutr Res. 2019; 65:54-62. DOI: 10.1016/j.nutres.2019.02.002. View